Food Science and Human Nutrition Department, University of Florida, Gainesville, FL.
Hepatology. 2013 Aug;58(2):788-98. doi: 10.1002/hep.26401. Epub 2013 Jul 1.
Divalent metal-ion transporter-1 (DMT1) is required for iron uptake by the intestine and developing erythroid cells. DMT1 is also present in the liver, where it has been implicated in the uptake of transferrin-bound iron (TBI) and non-transferrin-bound iron (NTBI), which appears in the plasma during iron overload. To test the hypothesis that DMT1 is required for hepatic iron uptake, we examined mice with the Dmt1 gene selectively inactivated in hepatocytes (Dmt1(liv/liv) ). We found that Dmt1(liv/liv) mice and controls (Dmt1(flox/flox) ) did not differ in terms of hepatic iron concentrations or other parameters of iron status. To determine whether hepatocyte DMT1 is required for hepatic iron accumulation, we crossed Dmt1(liv/liv) mice with Hfe(-) (/) (-) and hypotransferrinemic (Trf(hpx/hpx) ) mice that develop hepatic iron overload. Double-mutant Hfe(-) (/) (-) Dmt1(liv/liv) and Trf(hpx/hpx) ;Dmt1(liv/liv) mice were found to accumulate similar amounts of hepatic iron as did their respective controls. To directly assess the role of DMT1 in NTBI and TBI uptake, we injected (59) Fe-labeled ferric citrate (for NTBI) or (59) Fe-transferrin into plasma of Dmt1(liv/liv) and Dmt1(flox/flox) mice and measured uptake of (59) Fe by the liver. Dmt1(liv/liv) mice displayed no impairment of hepatic NTBI uptake, but TBI uptake was 40% lower. Hepatic levels of transferrin receptors 1 and 2 and ZRT/IRT-like protein 14, which may also participate in iron uptake, were unaffected in Dmt1(liv/liv) mice. Additionally, liver iron levels were unaffected in Dmt1(liv/liv) mice fed an iron-deficient diet.
Hepatocyte DMT1 is dispensable for hepatic iron accumulation and NTBI uptake. Although hepatocyte DMT1 is partially required for hepatic TBI uptake, hepatic iron levels were unaffected in Dmt1(liv/liv) mice, suggesting that this pathway is a minor contributor to the iron economy of the liver.
二价金属离子转运蛋白 1(DMT1)是肠道和正在发育的红细胞摄取铁所必需的。DMT1 也存在于肝脏中,它被认为与转铁蛋白结合铁(TBI)和非转铁蛋白结合铁(NTBI)的摄取有关,在铁过载期间,NTBI 会出现在血浆中。为了检验 DMT1 是否是肝脏铁摄取所必需的假设,我们研究了在肝细胞中选择性失活 Dmt1 基因的小鼠(Dmt1(liv/liv))。我们发现,Dmt1(liv/liv) 小鼠和对照(Dmt1(flox/flox))在肝铁浓度或其他铁状态参数方面没有差异。为了确定肝细胞 DMT1 是否是肝脏铁积累所必需的,我们将 Dmt1(liv/liv) 小鼠与 Hfe(-)(/)(-)和低转铁蛋白血症(Trf(hpx/hpx))小鼠杂交,这些小鼠会发展为肝脏铁过载。发现双突变 Hfe(-)(/)(-)Dmt1(liv/liv)和 Trf(hpx/hpx);Dmt1(liv/liv) 小鼠肝脏铁积累量与各自对照相似。为了直接评估 DMT1 在 NTBI 和 TBI 摄取中的作用,我们将(59)Fe 标记的柠檬酸铁(用于 NTBI)或(59)Fe 转铁蛋白注入 Dmt1(liv/liv)和 Dmt1(flox/flox) 小鼠的血浆中,并测量肝脏对(59)Fe 的摄取。Dmt1(liv/liv) 小鼠的肝 NTBI 摄取没有受损,但 TBI 摄取降低了 40%。Dmt1(liv/liv) 小鼠的转铁蛋白受体 1 和 2 和 ZRT/IRT 样蛋白 14 的肝水平不受影响,这些蛋白也可能参与铁摄取。此外,在喂食缺铁饮食的 Dmt1(liv/liv) 小鼠中,肝铁水平不受影响。
肝细胞 DMT1 对于肝脏铁积累和 NTBI 摄取不是必需的。尽管肝细胞 DMT1 部分需要用于肝脏 TBI 摄取,但 Dmt1(liv/liv) 小鼠的肝铁水平没有受到影响,这表明该途径是肝脏铁代谢的次要贡献者。